Back to results
US 2026/0028608 A1Published application
Cysteine protease
AssigneeHansa Biopharma AB
InventorsEmma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab′)2 fragments.
Claims14
A polypeptide having IgG cysteine protease activity and comprising or consisting of an amino acid sequence which is:
- (i) SEQ ID NO:
- 1;
- or
- (ii) SEQ ID NO:
- 2;
- or
- (iii) a variant of SEQ ID NO:
- 1 or SEQ ID NO:
- 2, which has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modification(s) relative to SEQ ID NO:
- 1 or SEQ ID NO:
- 2 respectively, provided that the sequence retains:
- (a) an asparagine (N) at the position which corresponds to position 95 of SEQ ID NO:
- 5, (b) an aspartic acid (D) at the position which corresponds to position 99 of SEQ ID NO:
- 5 and (c) an asparagine (N) at the position which corresponds to position 226 of SEQ ID NO:
- 5, and provided that the polypeptide is at least as effective at cleaving human IgG as the polypeptide consisting of the amino acid sequence of SEQ ID NOs:
- 1 or 2 respectively, when measured in the same assay.
13 more elements
Dependencies are inferred from the claim text.